Journal of the American Society of Hypertension
Research articleEffectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension
Introduction
Resistant hypertension, defined as uncontrolled hypertension despite treatment with three antihypertensive agents, is a common problem in clinical medicine and results in referrals from primary care physicians to hypertension specialists on a regular basis.1, 2 Recently, there have been observations that aldosterone blockade with spironolactone or amiloride is an effective strategy for reducing both systolic blood pressure (SBP) and diastolic blood pressure (DBP) when added to existing antihypertensive regimens in patients with resistant hypertension.3, 4 Furthermore, the addition of aldosterone antagonists has led to reductions in the overall number of antihypertensive medications. Despite these benefits, an important limiting factor for long-term utility of spironolactone has been its poor tolerability, especially in male patients at higher doses. The incidence of gynecomastia with concomitant sexual dysfunction in men increases to 10% to 30% with daily doses of 25 mg and higher.5, 6
Eplerenone is a highly selective aldosterone blocker with minimal sex hormone receptor activity.7 Eplerenone has a high degree of selectivity for the aldosterone receptor and a low binding affinity for progesterone (<1%) and androgen receptors (0.1%).7 Consequently, eplerenone is associated with a favorable tolerability profile with rates of gynecomastia, impotence, and menstrual cycle abnormalities similar to that of placebo.8, 9, 10, 11, 12 Because eplerenone has been shown to be an effective and well-tolerated agent when combined with renin-angiotensin blocking agents or diuretics when inadequate blood pressure (BP) control was observed,9, 10, 11 we hypothesized that it might be effective in patients with resistant hypertension who are taking these agents. To objectively evaluate the impact of eplerenone in this group of patients, we used ambulatory BP monitoring to evaluate the patient's response to therapy.13, 14 Because ambulatory BP monitoring removes all of the observer bias seen in antihypertensive drug trials and much of the “placebo” effect that is observed based on clinic measurements,14 we performed this trial with a prospective, open-label, blinded endpoint design as previously described.15
Section snippets
Study Design
The study was a prospective, open-label, two-center (Alabama and Connecticut) blinded endpoint (ambulatory BP measurements) clinical trial. After a screening visit, patients entered a 10- to 14-day run-in period to determine baseline BP stability. Ambulatory BP monitoring was used to establish the presence of true resistant hypertension (eg, vs. controlled hypertension and white-coat effect phenomenon). The screening period was followed by a 12-week, open-label treatment period in which
Patient Enrollment and Disposition
A total of 67 patients were screened for the study, of which 52 patients met all of the inclusion criteria and were initiated on eplerenone therapy. All patients who entered the eplerenone treatment phase of the study completed the trial. The two reasons for screening failures not qualifying for continuation in the study were out-of-range clinic BP values (n = 10) or ambulatory BP values (n = 5).
Baseline Characteristics of the Study Population
The baseline characteristics of the study population are shown in the Table. The mean age of the
Principal Findings
Results from this trial in patients with uncontrolled hypertension despite taking nearly four antihypertensive drugs demonstrated that eplerenone, a highly selective aldosterone antagonist, substantially and significantly lowered both clinic and ambulatory BP (Figure 1). Furthermore, the addition of eplerenone to a regimen of standard antihypertensive therapy that included a diuretic, renin-angiotensin blocking agent and in two-thirds of patients, a calcium antagonist, led to normalization of
Conclusions
This is the first study that has evaluated the effects of the selective aldosterone receptor blocking agent, eplerenone, in patients with resistant or difficult-to-control hypertension. Data derived from both clinic and ambulatory BP monitoring demonstrate that highly significant reductions in BP occurred with eplerenone and that the drug was very well tolerated. BP control rates were as high as 60% based on clinic BP values and 40% based on ambulatory BP values. These findings support the use
References (26)
- et al.
Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension
Am J Cardiol
(2003) - et al.
Effects of eplerenone versus losartan in patients with low-renin hypertension
Am Heart J
(2005) - et al.
Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting
Am Heart J
(2006) - et al.
Effects of controlled-onset extended-release verapamil on nocturnal blood pressure (dippers versus nondippers)COER-Verapamil Study Group
Am J Cardiol
(1997) - et al.
The role of spironolactone in the treatment of patients with refractory hypertension
Am J Hypertens
(2002) - et al.
Efficacy of low-dose spironolactone in subjects with resistant hypertension
Am J Hypertens
(2003) The 45-year story of the development of an anti-aldosterone more specific than spironolactone
Mol Cell Endocrinol
(2004)Resistant or difficult-to-treat hypertension
J Clin Hypertens
(2006)- et al.
Clinical practiceResistant or difficult-to-control hypertension
N Engl J Med
(2006) - et al.
The role of aldosterone in resistant hypertension: implications for pathogenesis and treatment
Curr Hypertens Rep
(2007)
Circadian blood pressure variation in hypertensive patients with primary hyperaldosteronism
Hypertension
Pathophysiology of spironolactone-induced gynecomastia
Ann Intern Med
Spironolactone and gynecomastia
Harvard Heart Lett
Cited by (111)
Resistant hypertension: Diagnosis, evaluation, and treatment practical approach
2024, European Journal of Internal MedicineResistant Hypertension
2023, Hypertension: A Companion to Braunwald's Heart DiseaseApproach to Resistant Hypertension from Cardiology and Nephrology Standpoints: Tailoring Therapy
2021, Cardiology ClinicsCitation Excerpt :A 50-patient study of eplerenone for the treatment of RH showed substantial BP lowering and was well tolerated. Interestingly, serum aldosterone and plasma renin activity did not predict BP responses to eplerenone in this study.35 A substudy of PATHWAY-2 assessed whether amiloride could be used as an alternative to spironolactone.
Special Article - The management of resistant hypertension: A 2020 update
2020, Progress in Cardiovascular DiseasesA New Era of Renal Denervation Trials for Patients With Hypertension?
2018, American Journal of Kidney Diseases
This article was supported by Pfizer, Inc (IIR no. 2004-0619) and by an unrestricted, investigator-initiated research Grant from University of Connecticut Health Center Clinical Trials Unit, Farmington, Connecticut.
Dr. Calhoun has served as a consultant to Novartis and is a member of the Pfizer speaker's bureau. Dr. White has served as a consultant to Pfizer on the topic of cardiovascular effects of arthritis therapies.